Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RESULTS ROUND-UP: Abiomed, Roche, Stryker positive; Siemens must do better

This article was originally published in Clinica

Executive Summary

As expected, the US FDA has approved Abiomed’s Impella RP percutaneous heart pump under a humanitarian device exemption for right-sided heart failure. The firm also reported 34% sales growth in its third fiscal quarter, at $62.0m, as worldwide Impella revenues shot up 37% to $57.4m. Jefferies analyst Raj Denhoy said it “could prove to be its breakout quarter. Revenues of $62m handily exceeded our $52m forecast.” He added: “The performance looks sustainable as the company is calling for 20% growth in FY16.”

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT102325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel